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Abstract
Background & Aims—Increasing evidence points towards a role of hepatitis C virus (HCV)
infection in causing malignant lymphomas. We pooled case-control study data to provide robust
estimates of the risk of non-Hodgkin’s lymphoma (NHL) subtypes after HCV infection.
Methods—The analysis included 7 member studies from the International Lymphoma
Epidemiology Consortium (InterLymph) based in Europe, North America, and Australia. Adult
cases of NHL (n = 4784) were diagnosed between 1988 and 2004 and controls (n = 6269) were
matched by age, sex, and study center. All studies used third-generation enzyme-linked
immunosorbent assays to test for antibodies against HCV in serum samples. Participants who were
human immunodeficiency virus positive or were organ-transplant recipients were excluded.
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Results—HCV infection was detected in 172 NHL cases (3.60%) and in 169 (2.70%) controls
(odds ratio [OR], 1.78; 95% confidence interval [CI], 1.40–2.25). In subtype-specific analyses,
HCV prevalence was associated with marginal zone lymphoma (OR, 2.47; 95% CI, 1.44–4.23),
diffuse large B-cell lymphoma (OR, 2.24; 95% CI, 1.68–2.99), and lymphoplasmacytic lymphoma
(OR, 2.57; 95% CI, 1.14–5.79). Notably, risk estimates were not increased for follicular
lymphoma (OR, 1.02; 95% CI, 0.65–1.60).
Conclusions—These results confirm the association between HCV infection and NHL and
specific B-NHL subtypes (diffuse large B-cell lymphoma, marginal zone lymphoma, and
lymphoplasmacytic lymphoma).
Hepatitis C virus (HCV) infection has been reported to be a prevalent disease since the
second half of the 20th century. The infection spread to the general population in some
countries such as Japan, Italy, and Egypt, with prevalence estimates ranging from 5% to
10%. In other developed countries the infection largely has been limited to individuals who
have received blood transfusions or are intravenous drug users with population prevalence
estimates ranging from 1% to 2%.1, 2 and 3
A causal role of HCV infection in cirrhosis and hepatocellular carcinoma is well established.
Also, HCV has been linked to lymphomagenesis in people with and without type II mixed
cryoglobulinemia.4 However, in the majority of lymphoma studies, small sample sizes have
prevented an analysis of the relationship between HCV and single lymphoma subtypes.
Increasing evidence indicates that the association between HCV infection and lymphoma
may be owing to viral infection–related chronic antigenic stimulation similar to that reported
for Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma.5 The
chronic inflammation pathway would be consistent with the association between HCV and
several types of lymphomas and with the regression of some lymphomas after eradicating
the HCV infection.6 and 7
We present results from a large international pooled analysis of the association between non-
Hodgkin lymphoma (NHL) and HCV in which HCV infection was determined using a third-
generation enzyme-linked immunosorbent assay test to measure HCV antibodies. Our study
includes data from 4784 NHL cases and 6269 controls from case-control studies
participating in the International Lymphoma Epidemiology Consortium (InterLymph).
MATERIALS AND METHODS
Study Population
InterLymph was established in 2000 as a voluntary consortium to facilitate collaboration
among epidemiologic studies of lymphoma (http://epi.grants.cancer.gov/InterLymph).8 and 9
Through the InterLymph Consortium, 7 case-control studies (3 were multicentric, for a total
of 17 participating centers) conducted between 1988 and 2004 were identified as eligible for
a pooled analysis. Studies were required to have used the third-generation enzyme-linked
immunosorbent assay test for HCV. Detailed information on the association between HCV
and NHL risk already has been published for 510, 11, 12, 13 and 14 of the 7 studies.
We hereafter refer to each contributing study as they have been published: Connecticut,
North–South Italy, National Cancer Institute (NCI)-surveillance epidemiology end result
(SEER), New South Wales (NSW), University of California San Francisco (UCSF),
EpiLymph (includes 6 countries in Europe), and British Columbia (Table 1). Selected
characteristics of each study, including acronym, study site, age range, selection criteria, and
participation rates, are presented in Table 1. Of the 17 study centers, 11 used population-
based controls and 6 used hospital-based controls. Cases and controls who were human
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immunodeficiency virus–positive or organ-transplant recipients were excluded from this
analysis. With the exception of the North–South Italy study, all studies frequency-matched
their cases and controls by age, sex, and study site. NCI-SEER also frequency-matched
cases and controls by race. Local institutional review boards approved all studies and written
informed consent was obtained from each participant.
Classification of Non-Hodgkin Lymphoma Subtypes
Four studies, British Columbia, NCI-SEER, NSW, and EpiLymph, used the World Health
Organization classification system to define lymphoid neoplasms.15 The studies conducted
in North–South Italy and Connecticut used the Revised European American Lymphoma
Classification (REAL) classification system to define NHL subtypes.16 The UCSF study
used both the REAL and the Working Formulation, and cases were recategorized into the
World Health Organization classification.
Classification systems from all studies were combined based on the International
Classification of Diseases for Oncology17 and 18 and the World Health Organization
classification-based categories developed within the InterLymph Pathology Working Group,
with the participation of representative pathologists from each major study.19 Eleven
subtypes were defined for subtypespecific analyses based on morphology and/or
immunohistochemistry information: small lymphocytic lymphoma and chronic lymphocytic
leukemia, mantle-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt
lymphoma, marginal zone lymphoma (MZL), follicular lymphoma (FL), lymphoplasmacytic
lymphoma (LPL), other B-cell lymphoma, Mycosis fungoides and Sézary syndrome, other
T-cell lymphoma, as well as NHL not otherwise specified (NHL NOS).
Statistical Analysis
A preliminary evaluation of categoric exposure variables and the overall NHL risk was
conducted using contingency tables analysis and the chi-square test of association.
Heterogeneity in risk estimates between study centers was assessed using the likelihood
ratio test under a logistic regression model. The model of interaction between countries and
exposure was compared with the model measuring the main effects only for outcomes
categorized as dichotomous or polytomous.20 When the P value of the chi-squared statistic
was less than .1021 the risk estimates were considered to be heterogeneous between study
centers.
A 2-stage estimation method was followed for risk of overall NHL; such a model allows the
control for confounding by individual studies and the consideration of random effects to
measure the unexplained interstudy variability.22 Study-specific risk estimates were
calculated using unconditional logistic regression adjusting for sex, age (<35, 35–44, 45–54,
55–64, and ≥65 y), and race (white, black, Asian, and other) because these variables were
used for matching in most of the original studies. In addition, any other confounders
identified in the preliminary analysis were included in the adjusted models. The study-
specific risk estimates obtained after adjustment were weighted by the inverse of the sum of
the variance of the individual study estimates to produce a second-stage pooled odds ratio
(OR).
For the subtype-specific analysis a joint fixed-effects model was used to allow the inclusion
of the studies that found zero HCV prevalence (ie, no cases of HCV infection) for a
particular NHL subtype. The risk estimates for specific lymphoma histology subtypes were
calculated using polytomous unconditional logistic regression models adjusted for the same
variables used in the overall NHL models. The results of lymphoma subtypes that were
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found to be associated with HCV infection or those with 10 or more HCV-infected cases are
presented graphically, plotting the study summary OR as a black square, whose size is
inversely proportional to the variance of the estimate. A horizontal line represents the 95%
confidence interval (CI). Diamonds are used to plot the summary OR (estimated using the
models described previously) for subtypes. The center of the diamond represents the pooled
OR and the extremes show the limits of the 95% CI. A log scale is used for the OR to
preserve the symmetry of the CI.
Sensitivity analyses were performed to compare pooled risk estimates after systematically
excluding each study to determine whether any single study unduly influenced the pooled
estimates. Statistical analyses of the data were conducted using STATA version 9.2
(StataCorp, College Station, TX).
RESULTS
The pooled study included 11,053 participants, 4784 cases and 6269 controls from 7 case-
control studies conducted in the United States, Europe, and Australia with information on
HCV infection (Table 1). Table 2 describes the prevalence of HCV for cases and controls by
sex, age, race, and history of blood transfusion. The pooled study population was
predominantly Caucasian (91.79%) and there were differences in the distribution by sex,
with a higher proportion of men compared with women (52.26% vs 47.74%). Among
controls, HCV was more prevalent among men than among women (3.18% vs 2.15%; P = .
012), and the prevalence was lower in Asians (0.0%), blacks (1.39%), and whites (2.61%)
compared with other ethnic groups (5.01%). Among both cases and controls, HCV was
related to transfusion history (ever transfusion vs never: P < .0001 and P = .003,
respectively). The overall prevalence of HCV was stable across age groups in all the studies
with the exception of the North–South Italy study that showed an increasing HCV
prevalence with increasing age (data not shown).
The pooled HCV prevalence was estimated to be 2.70% (range, 0.39%–10.0%) among
controls and 3.59% (range, 0%–30.6%) among cases (Figure 1). The study-specific
association between HCV and risk of NHL is presented in Table 3. In the pooled dataset,
NHL risk was increased in association with HCV positivity (OR, 1.78; 95% CI, 1.40–2.25).
The study-specific associations between HCV and risk of NHL are presented in Table 3; no
heterogeneity between the studies was identified (χ2 = 7.44; df = 6; P = .28). History of
transfusion was not related independently to lymphoma risk.
There was a wide range of HCV prevalence between the NHL subtypes, with the highest
value for Burkitt lymphoma (7.50%) and the lowest value for mantle-cell lymphoma
(0.84%) (Table 4). The effect of HCV positivity on risk of NHL varied within the B-cell
NHL subtype with the lowest risk noted for mantle-cell lymphoma and the highest for MZL.
In particular the risk estimate for DLBCL (OR, 2.24; 95% CI, 1.68–2.99) was statistically
different from the one for follicular lymphoma (OR, 1.02; 95% CI, 0.65–1.60). HCV
positivity was associated significantly with a statistically significant increase in risk of MZL
(OR, 2.47; 95% CI, 1.44–4.23), LPL (OR, 2.57; 95% CI, 1.14–5.79), DLBCL (OR, 2.24;
95% CI, 1.68–2.99), and “other B-cell lymphoma” (OR, 2.36; 95% CI, 1.11–5.01). The
“other B-cell lymphoma” category is a mixture of different subentities; the increased risk
was restricted to the B NHL NOS group. The risk of Burkitt lymphoma was increased
nonsignificantly 2-fold. HCV positivity did not appear to increase the risk of T-cell
lymphomas.
Study-specific analyses were performed for those lymphoma subtypes with a statistically
significant association with HCV (except the heterogeneous group of “other B-cell
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lymphomas”) or those with 10 or more cases exposed to HCV (Figure 2). Risk of LPL,
chronic lymphocytic leukemia, and FL associated with HCV infection did not differ among
studies whereas study differences were observed for DLBCL and MZL. The strongest
association between HCV and DLBCL was observed in British Columbia; however, the
sensitivity analysis showed no influence of any single study in the overall estimation of risk,
although the overall estimate was decreased by the absence of HCV infection among MZL
patients in the Connecticut and the NSW study populations. For MZL, a slightly increased
risk was observed when the EpiLymph study was excluded (OR, 4.84; 95% CI, 2.30–10.19)
and the opposite was observed when the North–South Italy study was excluded (OR, 1.96;
95% CI, 0.94–4.12). In Figure 2, no estimates are available for those lymphoma subtypes
with no HCV-positive cases.
DISCUSSION
This pooled analysis to explore the association between HCV infection and risk of NHL
subtypes included mostly countries with low background HCV prevalence with the
exception of Italy. Our results show increased risks of DLBCL, MZL, and LPL associated
with HCV infection. These risk estimates were particularly robust for DLBCL with a 2-fold
increased risk overall and a statistically significant increased risk observed in 3 of the 7
studies. Our results are in agreement with several studies mainly from Italy, a high-
prevalence country, which also found an association between HCV and
DLBCL,10, 11, 12, 13 and 23 MZL,24, 25 and 26 and LPL.27, 28 and 29
The association observed between HCV and MZL was strongest in the study conducted in
North–South Italy, with a 12-fold increased risk. However, sensitivity analyses showed that
the overall estimate was decreased by the absence of HCV infection among MZL patients in
the Connecticut and the NSW study populations. MZL is a subtype that was not defined
formally before the REAL classification30 and therefore the global incidence of MZL may
be underestimated when pooling studies using different classifications. Although the pooled
analysis included 385 MZL, with an overall 3-fold increase in risk, a more precise
evaluation of this association may require pooling of studies that each used the World
Health Organization classification to characterize MZL.
HCV infection was associated with a 3-fold increased risk of LPL. This association was
consistent in 4 of 6 studies with LPL cases. LPL includes immunocytoma and
Waldenström’s disease, both repeatedly identified as related to HCV infection in case-
control studies27, 28 and 29 and in a large cohort of US veterans.31 LPLs produce an
immunoglobulin M paraprotein with autoantibody or cryoglobulin activity. Interestingly,
these immunoglobulin Ms also may be present in MZL.15
Unlike 3 previous studies10, 11 and 25 and a recent meta-analysis,2 our pooled data did not
show an increased risk of FL associated with HCV infection, although risk of FL was
significantly lower than that of DLBCL. Differences may be owing to the different study
inclusion criteria. In the study presented here, we included only case-control studies that
used third-generation enzyme-linked immunosorbent assay testing and that provided the
individual study records. Other lymphoma subtypes that do not originate from germinal
center or postgerminal center B cells, such as mantle-cell lymphoma, Burkitt lymphoma, and
T-cell lymphoma, were not related consistently to HCV infection. Our results support the
hypothesis that proliferation of specific B-cell clones caused by chronic antigenic
stimulation sustained by HCV is a likely mechanism that drives the HCV-mediated
pathogenesis of B-cell lymphoma, in particular MZL and DLBCL.
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No clear mechanism of direct induction of malignancy by HCV in the lymphocyte
population has been shown consistently in vivo. Although earlier work6 showed lymphoma
remission after successful treatment of HCV in patients with splenic lymphoma with villous
lymphocytes, there are not yet any follow-up data from well-planned randomized trials to
clarify whether antiviral treatment is effective for the remission of lymphoproliferative
malignancy in hematologic HCV-positive patients.32 Such confirmation would imply a
benefit from a proven therapeutic tool, and confirm a strong association between HCV and
NHL.
Another line of evidence supporting the association between HCV and lymphoma is the
consistent association between HCV and mixed cryoglobulinemia. Chronic infection with
HCV is strongly associated with mixed cryoglobulinemia type II, which can evolve into
overt lymphoma in some patients.29, 33 and 34 Increasing evidence indicates that MZL of
mucosa-associated lymphoid tissue, both nodal and splenic types, are associated with
chronic antigenic stimulation by autoantigens and/or bacterial or viral pathogens. These
associations could not be tested in this study because no information was collected about
history of cryoglobulinemia. Our data warrant further investigation of this issue.
HCV does not integrate into the host genome and it does not contain an obvious oncogene.
Little is known about the mechanism of HCV in the activation and alterations of B-cell
functions leading to lymphomas. HCV envelope protein E2 interacts with CD81 on the
surface of B lymphocytes35 and with the B-cell receptor of HCV-associated lymphomas.36
This may jeopardize B-cell function and promote lymphomagenesis. New evidence suggests
an important role of HCV infection in the up-regulation of B-lymphocyte stimulator
(BLyS).37 BLyS is expressed by a variety of immune cells and acts on mature B
lymphocytes promoting differentiation, proliferation, and survival.38 and 39 BLyS transgenic
mice develop a lupus-like syndrome and finally B-cell lymphoma.40 and 41 Furthermore,
BLyS deregulation has been observed in patients with NHL42 as well as in several
autoimmune diseases that predispose to lymphomas including systemic lupus
erythromatosus,43 Sjögren’s syndrome,44 and rheumatoid arthritis,45 and in mixed
cryoglobulinemia syndrome.37 Interestingly, BLyS serum levels during chronic HCV
infection are correlated significantly with B-cell proliferation.46 Other contributing factors
for which some evidence exists include the following: (1) HCV-mediated induction of a
mutator phenotype with a substantial increase in mutation frequency in immunoglobulins
and proto-oncogenes,47 and 48 (2) down-regulation of major histocompatibility complex class
II molecules and apoptotic factors,49 and (3) activation of proinflammatory cytokine
production.50 and 51
As previously reported,52 the InterLymph consortium has allowed investigators to pool data
from contributing studies, providing adequate statistical power to test hypotheses using fully
adjusted models among participants without known immune suppression. These types of
initiatives are an excellent alternative when individual studies have low power to test
hypotheses related to rare exposures and within small subgroups.
Our results confirm the association between HCV infection and specific B-NHL subtypes
(DLBCL, MZL, and LPL). This study had sufficient statistical power to confirm these
associations in populations with low HCV prevalence. Our study further emphasizes the
need to implement strategic measures to prevent HCV infection and to treat HCV infection
adequately.
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Abbreviations used in this paper
BLyS B-lymphocyte stimulator
CI confidence interval
DLBCL diffuse large B-cell lymphoma
FL follicular lymphoma
HCV hepatitis C virus
InterLymph International Lymphoma Epidemiology Consortium
LPL lymphoplasmacytic lymphoma
MZL marginal zone lymphoma
NCI National Cancer Institute
NHL non-Hodgkin lymphoma
NOS not otherwise specified
NSW New South Wales
OR odds ratio
SEER Surveillance epidemiology end result
UCSF University of California San Francisco
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Prevalence of antibodies against HCV among NHL cases and their respective controls by
study.
de Sanjose et al. Page 10














Risk estimates for lymphoma sub-types associated with HCV by study. SLL/CLL, small-cell
lymphocytic lymphoma/chronic lymphocytic leukemia. (1) Heterogeneity test: χ2 = 11.69;
df = 6; P = .07. (2) Heterogeneity test: χ2 = 0.90; df = 3; P = .83. (3) Heterogeneity test: χ2 =
8.96; df = 6; P = .03. (4) Heterogeneity test: χ2 = 4.80; df = 6; P = .31. (5) Heterogeneity
test: χ2 = 7.79; df = 4; P = .10. †OR and 95% CI obtained from the polytomous
unconditional logistic regression using a joint fixed-effects model adjusted for age, sex, race,
and study center.
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Table 2








Included subjects 11,053 6269/4784 169(2.70) 172(3.60)
Sex
  Male 5776 (52.26) 3333/2443 106 (3.18) 97 (3.97)
  Female 5277 (47.74) 2936/2341 63 (2.15) 75 (3.2)
P valuea .01 .15
Age, y
  <35 860 (7.78) 594/266 11 (1.85) 7 (2.63)
  35–44 1280 (11.58) 792/488 23 (2.90) 23 (4.71)
  45–54 1959 (17.72) 1073/886 22 (2.05) 39 (4.40)
  55–64 2677 (24.22) 1415/1262 43 (3.04) 47 (3.72)
  ≥65 4277 (38.70) 2395/1882 70 (2.92) 56 (2.98)
P valuea .34 .18
Race
  White 10,146 (91.79) 5795/4351 151 (2.61) 157 (3.61)
  Asian 126 (1.14) 63/90 0 (0.0) 0 (0.0)
  Black 153 (1.38) 72/54 1 (1.39) 3 (5.56)
  Others 628 (5.68) 339/289 17 (5.01) 12 (4.15)
P valuea .03 .24
History of blood transfusion
  No 9001 (82.10) 5125/3876 123 (2.40) 117 (3.02)
  Yes 1899 (17.32) 1067/832 43 (4.03) 51 (6.13)
P valuea .003 <0.0001
a
Chi-squared association P value.
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